Aditxt, Inc. Insurance Commissions and Fees
Aditxt, Inc. (ADTX) reported Insurance Commissions and Fees of $507.02 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Notes › Financial Services
us-gaap:InsuranceCommissionsAndFees · last filed 2024-04-16
- Aditxt, Inc. insurance commissions and fees for the quarter ending 2023-12-31 was $0.00.
- Aditxt, Inc. insurance commissions and fees for the quarter ending 2023-09-30 was $0.00.
- Aditxt, Inc. insurance commissions and fees for the quarter ending 2023-06-30 was $0.00.
- Aditxt, Inc. insurance commissions and fees for the quarter ending 2023-03-31 was $507.02K.
- Aditxt, Inc. insurance commissions and fees for fiscal 2023 was $507.02K.
| Period end | Insurance Commissions and Fees 3 month | Insurance Commissions and Fees 6 month | Insurance Commissions and Fees 9 month | Insurance Commissions and Fees 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $0.00 derived: sum of 2 quarters · filed 2024-04-16 | $0.00 derived: sum of 3 quarters · filed 2024-04-16 | $507.02K 10-K · filed 2024-04-16 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $507.02K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $507.02K 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $507.02K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |